Insilico Medicine stories

Sep 7, 2026

AI-designed drug shows promise in reversing biological aging markers in clinical trial

Insilico Medicine announced that rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reduce biological age markers in a 42-patient trial. Six independently built aging clocks all showed patients on the drug appeared biologically younger, according to a study conducted with researchers from Harvard Medical School, Stanford University, and The Broad Institute.

Sep 7, 20264 sources

Jul 23, 2026

Insilico CEO Says AI Cuts Time to Drug Candidate to About One Year in China

Insilico Medicine CEO Alex Zhavoronkov told Reuters that the company typically reaches a developmental drug candidate in 13 months, with a record of nine months, by combining AI with its research operations in China. Reuters reported that China has become a major hub for next-generation medicine development, aided by lower research costs and streamlined regulation.

Jul 23, 20266 sources